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A deadly prescription: combination of methotrexate and
trimethoprim-sulfamethoxazole
Mohsin Hamid a, Bilal Lashari a, Irfan Ahsan a, Ida Micaily a, Usman Sarwara and Joseph Crocettib
aDepartment of Internal Medicine, Abington Hospital–Jefferson Health, Abington, PA, USA; bPulmonary and Critical Care, Abington
Hospital–Jefferson Health, Abington, PA, USA
ABSTRACT
Methotrexate (MTX) is a chemotherapeutic synthetic(s) phase cell cycle inhibitor, and its role
has evolved as an immunological agent in autoimmune diseases like rheumatoid arthritis,
psoriasis, and systemic lupus erythematosus, etc. Trimethoprim-sulfamethoxazole (TS) is one
of the most widely prescribed antibiotics commonly used for urinary tract infections, exacer-
bations of chronic bronchitis, traveler’s diarrhea, and pneumocystis pneumonia. Both MTX
and TS can have significantly overlapping side effects involving dermatologic, renal, and
hematological systems, and the combination of these can be deadly. Our case is about the
combination of MTX and TS that leads to mucocutaneous ulceration, leukopenia, and renal
insufficiency. The purpose of this case is to increase awareness of potentially significant
toxicity from the combination of MTX with TS.
Abbreviations: MTX: methotrexate; TS: trimethoprim-sulfamethoxazole; ED: emergency
department; IV: intravenous; GI: gastrointestinal; NSAIDs: nonsteroidal anti-inflammatory drugs.
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drug interaction; folinic acid
rescue; pancytopenia
1. Introduction
Methotrexate (MTX) is a chemotherapeutic synthetic(s)
phase cell cycle-specific inhibitor that preferentially tar-
gets actively proliferating tissues. It irreversibly binds
and inhibits dihydrofolate reductase enzyme and
impairs the ability of the DNA to replicate. Being the
first chemotherapeutic agent shown to have a response
in cancer treatment, it changed the world of chemother-
apy as we know it and led to the development of many
standard cancer treatments used today [1-3]. The role of
MTX has evolved as an immunological agent in auto-
immune diseases such as rheumatoid arthritis, psoria-
sis, and systemic lupus erythematosus, etc. The most
common adverse effects include gastrointestinal (GI)
upset, stomatitis, rash, neurological symptoms (head-
ache, fatigue, agitation), mild transaminitis, and macro-
cytosis [4]. As an immunological agent, lower doses are
used; however, toxicities can still occur due to interac-
tions with other medications or impairments in renal
and hepatic metabolism.
Trimethoprim-sulfamethoxazole (TS) is one of the
most widely prescribed antibiotic medications and
works as a bacteriostatic antimicrobial by inhibiting
sequential enzymes in the folic acid pathway.
Sulfamethoxazole blocks the formation of dihydrofo-
lic acid from its precursors, and trimethoprim blocks
the reduction of dihydrofolate into tetrahydrofolate.
It is commonly used for conditions such as urinary
tract infections, exacerbations of chronic bronchitis,
traveler’s diarrhea, and pneumocystis pneumonia. Its
potential toxicities include nephrotoxicity, hyperkale-
mia, pancytopenia, neutropenia, skin rash, and
Steven Johnson’s syndrome many of which overlap
with the toxicity of MTX [5]. We are presenting this
case to increase awareness of the potentially signifi-
cant toxicity of MTX due to its interaction TS.
2. Case presentation
A 68-year-old female with a history of rheumatoid
arthritis on 10 mg MTX weekly presented to the emer-
gency department (ED) with weakness, lethargy, and
decreased oral intake. Two weeks prior to presentation,
her primary care physician (PCP) prescribed a 2-week
course of TS for presumed bacterial skin infection
under her left breast. One week after starting therapy,
she noticed painful oral sores and flu-like symptoms.
In the ED, she was hypotensive to 90/60 mm Hg but
responded to intravenous (IV) fluids. Vital signs were
otherwise stable. The pertinent physical exam included
severe oral mucositis, lip ulceration, and an erythema-
tous rash under her left breast. Laboratory data
revealed creatinine: 2.39 mg/dl (baseline 0.7 mg/dL),
potassium: 5.3 mEq/L, chloride: 97 mEq/L, leukocyte
count: 3.2 K/uL, absolute neutrophil count: 2.8 K/uL,
hemoglobin: 12.3 mg/dL, and platelet count: 230 K/uL.
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TS was held as the symptoms of mucocutaneous
ulceration, leukopenia, and renal insufficiency were
initially attributed to possible TS toxicity and suppor-
tive care with IV fluids and oral care was given. Her
oral ulcers remained unresolved; leukocyte count con-
tinued to drop reaching a nadir of 1.9 K/uL and abso-
lute neutrophil count dipped to 0.7 K/uL over the
course of next 2 days. Renal function, however,
improved with IV hydration. After consultation with
hematology, a careful review of patient’s medications
list and drug interactions were done, and her symp-
toms were attributed to MTX–TS interaction leading
to MTX toxicity rather than toxicity of TS itself. MTX
levels were sent that came back high at 0.5 µmol/L.
Leucovorin rescue was given at the dose of 10 mg/m2
every 6 h for a total of four doses with one dose of
Filgrastim 480 mcg which resulted in the improvement
of the leukocyte count, breast rash, and mouth ulcers
within 24 h. The patient was discharged on day 6 of
hospitalization and did well post discharge.
3. Discussion
The first serious interaction between TS and MTX was
reported in 1986 by Thomas [6]. Since then, numerous
case reports and observational studies have been pub-
lished but the combination is still prescribed and in
many instances has led to fatal consequences [7,8].
After oral administration, MTX is absorbed quickly,
the kidneys excrete 80–90%and liver enzymesmetabolize
the rest. A positive correlation has been noticed between
MTX clearance and creatinine clearance and hence
abnormal renal function can precipitate MTX toxicity.
After filtration by glomeruli, it undergoes both secretion
and reabsorption and competes with other drugs during
this process. It accumulates in third spaces such as pleura
and peritoneum and is eliminated slowly from these
spaces as compared to plasma, and the dosage needs to
be readjusted in these situations. The primary metabolite
is 90% bound to plasma proteins and therefore can have
extensive drug interactions. Most commonly co-
prescribed drugs with MTX are steroids, aspirin (ASA),
and nonsteroidal anti-inflammatory drugs (NSAIDs).
Steroids have been shown to be safe with MTX.
NSAIDs and high dose ASA decrease the renal excretion
ofMTX and increase its plasma concentration. However,
a systematic review found that concurrent use of most
NSAIDs with MTX is safe, yet, anti-inflammatory doses
of ASA should not be usedwithMTX [9]. Folate has been
shown to reduce the toxicity of MTX especially GI and
liver toxicity without affecting the efficacy of MTX
through unknown mechanisms [10,11].
Multiple case reports and other observational
studies have noted severe interaction between
MTX and TS [6–8,9,12–19]. When used together,
TS can increase MTX’s toxicity. Although the
exact mechanism is unknown, synergistic folate
antagonism, competitive tubular secretion, and dis-
placement from albumin binding site might explain
it [8,20–22]. One study pointed out an increase of
about 60% of free MTX concentration in blood
when used concurrently with TS [15]. The most
commonly reported toxicity of MTX due to its
interaction with TS is pancytopenia, acute megalo-
blastic anemia, stomatitis, and nephrotoxicity [19].
Other case reports have also shown rare side effects
such as toxic epidermal necrolysis [23]. Care
should be taken not to confuse toxicity of MTX
with TS as TS has similar side effect profile namely
nephrotoxicity, pancytopenia, and Steven Johnson’s
syndrome. In the case of possible MTX toxicity,
serum levels should be checked and if found to be
high, aggressive IV hydration, urinary alkalization,
and folinic acid rescue should be initiated. Therapy
should be continued until the MTX dose levels
have dropped to 0.05–0.1 µmol/L or less.
It has however been noticed that prophylactic dose
of TS does not have any significant interaction when
used concurrently with MTX and can be co-
prescribed safely.
Medical health professional needs to be aware of
the differences between the toxicity of MTX and TS
and their potential interaction so that they will not
falsely attribute the toxicity of MTX to TS.
4. Conclusion
With the available current literature, it is prudent to
say that the combination of MTX and TS should be
avoided, as it can lead to significant morbidity and
possibly mortality. To prevent this combination, pri-
mary care doctors need to be educated about this
deadly combination as the prescription of TS in out-
patient clinics usually bypasses the pharmacy-based
safety checkpoints. The patients taking MTX should
be instructed about the potential side effects and
interactions so that prompt identification and discon-
tinuation can be done to prevent serious harm.
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